Generalized Anxiety Disorder Clinical Trial
Official title:
A Single Blind, Parallel Arm, Single Institution Pivotal RCT to Test Safety and Efficacy of Digital Therapeutics 'ANZEILAX' for Managing Generalized Anxiety Disorder
Verified date | August 2023 |
Source | HAII corp.ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators propose to develop and adapt 'ANZEILAX' smartphone app specifically for individuals with Generalized anxiety disorder. The study will measure the therapeutic effects and safety of 'ANZEILAX' on symptoms of anxiety using pre- and post-treatment scores for generalized anxiety disorder and other physical, emotional, and cognitive symptoms of anxiety
Status | Recruiting |
Enrollment | 96 |
Est. completion date | April 4, 2024 |
Est. primary completion date | February 29, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: People can participate in this clinical trial only if following criteria are met. 1. Adults aged 19 years or older with a high school diploma or higher 2. Disease groups according to the criteria below: - A person diagnosed with Generalized Anxiety Disorder (DSM-5 (ICD-10) code: 300.02 (F41.1)) - Those who are classified as moderate or severe with 10 points or more through GAD-7 - Those taking prescription drugs related to generalized anxiety disorder 3. A group of disorders with generalized anxiety disorder, or a group of disorders with worry that is a major symptom of generalized anxiety disorder in any of the following criteria: - Those suffering from other anxiety disorders such as panic disorder and social anxiety disorder - Those suffering from major depressive disorder accompanied by worry, the main symptom of generalized anxiety disorder 4. A person who fully understands the purpose, contents, and process of the clinical trial, agrees to participate, and signs the consent form in handwriting Exclusion Criteria: If any of the following criteria is applicable, the person cannot participate in this clinical trial. 1. Those who cannot read the consent form 2. Those who are inexperienced in using smartphones 3. In case of psychiatric symptoms or history (including schizophrenia, psychosis, bipolar disorder, epilepsy) 4. In case of brain damage, cognitive impairment, or neurological disease 5. In case of intellectual disability 6. Having a substance and alcohol use disorder 7. Suicidal intent, suicidal ideation, or self-injurious behavior in the past 6 months 8. Receiving cognitive behavioral therapy for anxiety, depression or mood disorders, or participating in such therapy in the past 3 months 9. Those who are registered in other clinical studies 10. Other investigators judged that the conduct of this clinical trial was inappropriate |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Yonsei University Health System, Gangnam Severance Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
HAII corp.ltd |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Generalized Anxiety Disorder-7 | Baseline assessment, Week 5, Week 10, Week 15 | ||
Secondary | Beck Anxiety Inventory | Baseline assessment, Week 5, Week 10, Week 15 | ||
Secondary | Penn State Worry Questionnaire | Baseline assessment, Week 5, Week 10, Week 15 | ||
Secondary | Hospital Anxiety and Depression Scale | Baseline assessment, Week 5, Week 10, Week 15 | ||
Secondary | Treatment adherence | Week 5, Week 10 | ||
Secondary | Satisfaction evaluation | Week 5, Week 10 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03420456 -
Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study
|
N/A | |
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Withdrawn |
NCT02382224 -
Worry Exposure for Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT02256566 -
Cognitive Training for Mood and Anxiety Disorders
|
N/A | |
Completed |
NCT02306356 -
Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting
|
N/A | |
Completed |
NCT01958788 -
Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01681329 -
Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01201967 -
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
|
Phase 4 | |
Completed |
NCT01337713 -
Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)
|
N/A | |
Completed |
NCT01342120 -
PHARMO Institute Seroquel Safety Study
|
N/A | |
Completed |
NCT00961298 -
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
|
Phase 4 | |
Completed |
NCT01971203 -
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
|
N/A | |
Completed |
NCT01203293 -
Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector
|
Phase 1 | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00744627 -
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
|
Phase 3 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00515242 -
Therapeutic Massage for Generalized Anxiety Disorder
|
Phase 1/Phase 2 | |
Completed |
NCT00537615 -
An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00620776 -
Combined Treatment for Generalized Anxiety Disorder (GAD)
|
Phase 2 |